Journal Article

Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis

Rajasingham, Radha, Chiller, Tom M., Nakawuka, Mina, Jordan, Alexander, Boulware, David R., Greene, Gregory S., Larson, Bruce A., Meya, David B.

2019

Overview

Cryptococcal meningitis accounts for 15% of AIDS-related mortality. Cryptococcal antigen (CrAg) is detected in blood weeks before onset of meningitis, and CrAg positivity is an independent predictor of meningitis and death. CrAg screening for patients with advanced HIV and preemptive treatment is recommended by the World Health Organization, though implementation remains limited. Our objective was to evaluate costs and mortality reduction (lives saved) from a national CrAg screening program across Uganda. We created a decision analytic model to evaluate CrAg screening. CrAg screening was considered for those with a CD4<100 cells/μL per national and international guidelines, and in the context of a national HIV test-and-treat program where CD4 testing was not available. Costs (2016 USD) were estimated for screening, preemptive therapy, hospitalization, and maintenance therapy. Parameter assumptions were based on large prospective CrAg screening studies in Uganda, and clinical trials from sub Saharan Africa. CrAg positive (CrAg+) persons could be: (a) asymptomatic and thus eligible for preemptive treatment with fluconazole; or (b) symptomatic with meningitis with hospitalization. In the base case model for 1 million persons with a CD4 test annually, 128,000 with a CD4<100 cells/μL were screened, and 8,233 were asymptomatic CrAg+ and received preemptive therapy. Compared to no screening and treatment, CrAg screening and treatment in the base case cost $3,356,724 compared to doing nothing, and saved 7,320 lives, for a cost of $459 per life saved, with the $3.3 million in cost savings derived from fewer patients developing fulminant meningitis. In the scenario of a national HIV test-and-treat program, of 1 million HIV-infected persons, 800,000 persons were screened, of whom 640,000 returned to clinic, and 8,233 were incident CrAg positive (CrAg prevalence 1.4%). The total cost of a CrAg screening and treatment program was $4.16 million dollars, with 2,180 known deaths. Conversely, without CrAg screening, the cost of treating meningitis was $3.09 million dollars with 3,806 deaths. Thus, despite the very low CrAg prevalence of 1.4% in the general HIV-infected population, and inadequate retention-in-care, CrAg screening averted 43% of deaths from cryptococcal meningitis at a cost of $662 per death averted. CrAg screening and treatment programs are cost-saving and lifesaving, assuming preemptive treatment is 77% effective in preventing death, and could be adopted and implemented by ministries of health to reduce mortality in those with advanced HIV disease. Even within HIV test-and-treat programs where CD4 testing is not performed, and CrAg prevalence is only 1.4%, CrAg screening is cost-effective.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Acquired immune deficiency syndrome / Adult / AIDS / AIDS-Related Opportunistic Infections - blood / AIDS-Related Opportunistic Infections - diagnosis / AIDS-Related Opportunistic Infections - mortality / AIDS-Related Opportunistic Infections - prevention & control / Antifungal agents / Antifungal Agents - administration & dosage / Antigens, Fungal - blood / Biology and Life Sciences / CD4 antigen / CD4 Lymphocyte Count / Clinical trials / Cost analysis / Cost engineering / Cost-Benefit Analysis / Cryptococcal meningitis / Cryptococcus - immunology / Cryptococcus - isolation & purification / Death / Decision analysis / Decision Support Techniques / Disease control / Fatalities / Fluconazole / Fungal infections / Health aspects / HIV / HIV infections / Hospitalization - economics / Human immunodeficiency virus / Humans / Mass Screening - economics / Mass Screening - methods / Mass Screening - standards / Mass Screening - statistics & numerical data / Mathematical models / Medical diagnosis / Medical research / Medicine and Health Sciences / Meningitis / Meningitis, Cryptococcal - blood / Meningitis, Cryptococcal - diagnosis / Meningitis, Cryptococcal - mortality / Meningitis, Cryptococcal - prevention & control / Models, Economic / Mortality / Patients / Practice Guidelines as Topic / Preempting / Prevalence / Preventable deaths / Program Evaluation / Prospective Studies / Quality-Adjusted Life Years / Screening / Therapy / Treatment Outcome / Uganda - epidemiology